Table 2.
Adjuvant treatment
| Characteristic | # patients (%) | |
|---|---|---|
| Time between resection and adjuvant therapy (days) |
Median: | 55 |
| Range: | 33–119 | |
| ECOG performance status at initiation of therapy |
0 | 52 (60%) |
| 1 | 28 (33%) | |
| 2 | 2 (2%) | |
| Unknown | 4 (5%) | |
| BMI prior to adjuvant treatment* | Median: | 24.7 |
| Range: | 17.5-37.8 | |
| Follow-up from resection (months) among 20 patients still alive |
Median: | 31 |
| Range: | 21–62 | |
| RT Dose: (cGy) | <5040 | 6 (7%) |
| 5040 | 73 (85%) | |
| 5400 | 7 (8%) | |
| Concurrent 5-FU with RT | Continuous infusion | 78 (91%) |
| Bolus injection | 7 (8%) | |
| Capecitabine§ | 1 (1%) | |
| Other Adjuvant Chemotherapy# | Gemcitabine‡ | 39 (45%) |
| 5-FU + Leucovorin | 13 (15%) | |
| Continuous 5-FU post-RT | 1 (1%) | |
| FOLFOX† | 1 (1%) | |
Abbreviations: ECOG= Eastern Cooperative Oncology Group; BMI= body mass index; 5-FU= 5-fluorouracil; RT= radiation therapy
*
Post-operative BMI, prior to adjuvant chemoradiation
§
Capecitabine (XELODA®), Hoffmann-La Roche Inc, Nutley, NJ, USA
#
Patients who received other adjuvant chemotherapy following concurrent chemotherapy and radiation
‡
4 patients who received gemcitabine received additional adjuvant chemotherapy (i.e. 3 received leucovorin, 1 received FOLFOX)
†
One patient received gemcitabine + FOLFOX [leucovorin, 5-FU, and oxaliplatin (Eloxatin®) Sanofi-Aventis, Paris, France]